Morbidity and Functional Outcomes Following Rocky Mountain Spotted Fever Hospitalization-Arizona, 2002-2017.

Rickettsia neurology sequela tick

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 14 07 2022
accepted: 30 09 2022
entrez: 3 11 2022
pubmed: 4 11 2022
medline: 4 11 2022
Statut: epublish

Résumé

Rocky Mountain spotted fever (RMSF) is a deadly tickborne disease disproportionately affecting Arizona tribal communities. While the acute clinical effects of RMSF are well-documented, more complete understanding of the long-term health consequences is needed to provide guidance for providers and patients in highly impacted areas. We performed a retrospective review of hospitalized RMSF cases from 2 tribal communities in Arizona during 2002-2017. Medical records from acute illness were abstracted for information on clinical presentation, treatment, and status at discharge. Surviving patients were interviewed about disease recovery, and patients reporting incomplete recovery were eligible for a neurologic examination. Eighty hospitalized cases of RMSF met our inclusion criteria and were reviewed. Of these, 17 (21%) resulted in a fatal outcome. Among surviving cases who were interviewed, most (62%) reported full recovery, 15 (38%) reported ongoing symptoms or reduced function following RMSF illness, and 9 (23%) had evidence of neurologic sequelae at the time of examination. Sequelae included impaired cognition, weakness, decreased deep tendon reflexes, seizures, and cranial nerve dysfunction. Longer hospitalization (25.5 days vs 6.2 days, Although the etiology of sequelae is not able to be determined using this study design, life-altering sequelae were common among patients surviving severe RMSF illness. Delayed administration of the antibiotic doxycycline after day 5 was the strongest predictor of morbidity.

Sections du résumé

Background UNASSIGNED
Rocky Mountain spotted fever (RMSF) is a deadly tickborne disease disproportionately affecting Arizona tribal communities. While the acute clinical effects of RMSF are well-documented, more complete understanding of the long-term health consequences is needed to provide guidance for providers and patients in highly impacted areas.
Methods UNASSIGNED
We performed a retrospective review of hospitalized RMSF cases from 2 tribal communities in Arizona during 2002-2017. Medical records from acute illness were abstracted for information on clinical presentation, treatment, and status at discharge. Surviving patients were interviewed about disease recovery, and patients reporting incomplete recovery were eligible for a neurologic examination.
Results UNASSIGNED
Eighty hospitalized cases of RMSF met our inclusion criteria and were reviewed. Of these, 17 (21%) resulted in a fatal outcome. Among surviving cases who were interviewed, most (62%) reported full recovery, 15 (38%) reported ongoing symptoms or reduced function following RMSF illness, and 9 (23%) had evidence of neurologic sequelae at the time of examination. Sequelae included impaired cognition, weakness, decreased deep tendon reflexes, seizures, and cranial nerve dysfunction. Longer hospitalization (25.5 days vs 6.2 days,
Conclusions UNASSIGNED
Although the etiology of sequelae is not able to be determined using this study design, life-altering sequelae were common among patients surviving severe RMSF illness. Delayed administration of the antibiotic doxycycline after day 5 was the strongest predictor of morbidity.

Identifiants

pubmed: 36324320
doi: 10.1093/ofid/ofac506
pii: ofac506
pmc: PMC9605701
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac506

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Déclaration de conflit d'intérêts

Potential conflicts of interest. The authors: No reported conflicts of interest.

Références

MMWR Recomm Rep. 2016 May 13;65(2):1-44
pubmed: 27172113
J Pediatr. 2007 Feb;150(2):180-4, 184.e1
pubmed: 17236897
Ann N Y Acad Sci. 2003 Jun;990:1-11
pubmed: 12860594
Am J Public Health Nations Health. 1938 Dec;28(12):1411-4
pubmed: 18014958
Am J Trop Med Hyg. 2015 Sep;93(3):549-551
pubmed: 26033020
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Med Res. 1919 Nov;41(1):1-198.41
pubmed: 19972499
Emerg Infect Dis. 2021 Jun;27(6):
pubmed: 34014151
Clin Infect Dis. 2015 Jun 1;60(11):1650-8
pubmed: 25697743
Univ Hosp Bull. 1948 Mar;14(3):22
pubmed: 18915001
Clin Infect Dis. 2015 Jun 1;60(11):1659-66
pubmed: 25697742
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
AMA Arch Intern Med. 1952 Oct;90(4):444-55
pubmed: 12975878
Clin Infect Dis. 1995 May;20(5):1122-5
pubmed: 7619986
J Infect Dis. 1984 Oct;150(4):480-8
pubmed: 6491365
Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):38-43
pubmed: 22698678
Neurology. 2011 Sep 27;77(13):1272-5
pubmed: 21917776
Clin Infect Dis. 1995 May;20(5):1118-21
pubmed: 7619985
Pediatrics. 1981 Mar;67(3):354-7
pubmed: 7243471
J Vector Borne Dis. 2020 Apr-Jun;57(2):114-120
pubmed: 34290155
J Infect Dis. 2001 Dec 1;184(11):1437-44
pubmed: 11709786
Pediatr Infect Dis J. 2015 Feb;34(2):125-30
pubmed: 25126856

Auteurs

Naomi A Drexler (NA)

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ryan Close (R)

Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.

Hayley D Yaglom (HD)

Pathogen and Microbiome Division, Translational Genomics Research Institute, Flagstaff, Arizona, USA.
Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.

Marc Traeger (M)

Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.

Kristen Parker (K)

Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.

Heather Venkat (H)

Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.
Center for Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lisa Villarroel (L)

Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.

Jeanette Brislan (J)

Gila River Healthcare Public Health Nursing, Sacaton, Arizona, USA.

Daniel M Pastula (DM)

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
University of Colorado School of Medicine and Colorado School of Public Health, Aurora, Colorado, USA.

Paige A Armstrong (PA)

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Classifications MeSH